<DOC>
	<DOCNO>NCT02668640</DOCNO>
	<brief_summary>The study non-interventional , observational study assess effect Adalimumab health-related quality life work productivity patient Rheumatoid Arthritis ( RA ) China .</brief_summary>
	<brief_title>Real-World Outcome Adalimumab Rheumatoid Arthritis Patients China</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participant diagnosis RA define 1987 revised American College Rheumatology ( ACR ) classification criterion and/or ACR/the European League Rheumatism ( EULAR ) 2010 classification criterion ( duration since diagnosis ) . Participants moderate severe RA define Disease Activity Score 28 Joints ( DAS28 ) Erythrocyte Sedimentation Rate ( ESR ) DAS28 CReactive Protein ( CRP ) &gt; 3.2 Biologically treatment na√Øve initiate adalimumab baseline visit , per standard daily clinical practice . Availability clinical data previous 12 week prior week 0 ( baseline ) . Ability selfcomplete patient questionnaire . Participants sign authorization ( informed consent applicable ) disclose use personal health information prescribe adalimumab . Participants pregnant breast feeding enrolment wish become pregnant next 24 week . Participation RArelated clinical trial time enrolment , baseline point past 24 week prior baseline Participants , clinician 's view , may able accurately report quality life ( QoL ) prior resource utilization Participants , clinician 's view , may able adhere Adalimumab therapy 24 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Work productivity</keyword>
	<keyword>Rheumatoid arthritis ( RA )</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Quality life ( QOL )</keyword>
</DOC>